| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 191.12B | 181.30B | 210.22B | 233.88B | 273.68B | 254.76B |
| Gross Profit | 37.56B | 32.71B | 37.45B | 39.84B | 65.73B | 66.81B |
| EBITDA | 27.05B | 30.80B | 26.54B | 28.36B | 56.67B | 52.56B |
| Net Income | 8.84B | 2.90B | 4.41B | 8.82B | 17.09B | 13.55B |
Balance Sheet | ||||||
| Total Assets | 505.74B | 494.01B | 488.90B | 482.47B | 462.54B | 456.38B |
| Cash, Cash Equivalents and Short-Term Investments | 30.69B | 32.96B | 37.37B | 35.06B | 35.52B | 35.87B |
| Total Debt | 208.06B | 194.48B | 187.03B | 176.29B | 169.81B | 178.40B |
| Total Liabilities | 312.96B | 299.48B | 295.38B | 290.13B | 283.92B | 291.20B |
| Stockholders Equity | 116.37B | 119.44B | 123.16B | 123.15B | 118.68B | 108.88B |
Cash Flow | ||||||
| Free Cash Flow | 21.15B | 1.40B | 6.98B | -4.72B | 13.16B | 36.38B |
| Operating Cash Flow | 30.49B | 23.20B | 29.02B | 26.35B | 50.09B | 64.23B |
| Investing Cash Flow | -10.95B | -20.28B | -27.34B | -25.68B | -35.61B | -29.34B |
| Financing Cash Flow | -14.24B | -6.57B | -1.08B | -2.18B | -16.72B | -28.88B |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
66 Neutral | HK$46.07B | 8.24 | 10.69% | 4.82% | 0.40% | 62.35% | |
65 Neutral | HK$139.79B | 9.48 | 4.59% | 4.59% | -28.50% | 23.92% | |
63 Neutral | HK$43.96B | 1.73 | 7.49% | 3.30% | -5.50% | 1248.29% | |
61 Neutral | $10.43B | 7.12 | -0.05% | 2.87% | 2.86% | -36.73% | |
60 Neutral | HK$11.58B | 2.51 | 7.90% | 1.29% | 20.56% | 254.64% | |
49 Neutral | HK$2.22B | -2.49 | -5.53% | ― | -14.85% | ― | |
48 Neutral | HK$727.65M | 2.64 | 2.06% | ― | 0.18% | ― |
China National Building Material has issued a profit warning, flagging an expected unaudited net loss attributable to equity holders of between RMB2.3 billion and RMB4.0 billion for 2025, a sharp reversal from the profit of about RMB2.387 billion recorded in 2024. Management attributes the downturn chiefly to substantial impairment losses on property, plant and equipment and goodwill tied to exiting certain cement clinker production lines under capacity replacement measures, with total asset impairment for 2025 estimated at RMB6.0 billion to RMB8.3 billion. Weaker cement sales volumes, despite lower costs, further weighed on performance, though this was partly offset by improved pricing and cost reductions in glass fiber, higher sales of wind power blades and coatings, and increased profit contributions from associates. The company cautioned investors that the figures are preliminary and unaudited, and advised shareholders and potential investors to exercise caution when trading its shares ahead of the final 2025 results due by end-March 2026.
The most recent analyst rating on (HK:3323) stock is a Hold with a HK$6.00 price target. To see the full list of analyst forecasts on China National Building Material Co stock, see the HK:3323 Stock Forecast page.
China National Building Material has disclosed that its subsidiary Sinoma Science & Technology expects a sharp increase in profitability for the 12 months ended 31 December 2025, with estimated net profit attributable to shareholders rising to between RMB1.55 billion and RMB1.95 billion, up 73.79% to 118.64% from a year earlier, and net profit after deducting non-recurring items projected to climb 173.76% to 251.97%. The unaudited estimate, based on preliminary internal calculations, reflects an improved product mix and higher prices for glass fiber products as well as higher sales volumes of wind power blades, underscoring Sinoma Science & Technology’s strengthening position in high-value new materials and signalling potentially stronger earnings contributions to the parent group if these trends are maintained.
The most recent analyst rating on (HK:3323) stock is a Buy with a HK$5.90 price target. To see the full list of analyst forecasts on China National Building Material Co stock, see the HK:3323 Stock Forecast page.